CoChat

Implications and limitations of cellular reprogramming for psychiatric drug development

Tobe, Brian T D, Brandel, Michael G, Nye, Jeffrey S, Snyder, Evan Y · 2013 · Experimental & Molecular Medicine
Cited by 9

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Human-induced pluripotent stem cells (hiPSCs) derived from somatic cells of patients have opened possibilities for in vitro modeling of the physiology of neural (and other) cells in psychiatric disease states. Issues in early stages of technology development include (1) establishing a library of cells from adequately phenotyped patients, (2) streamlining laborious, costly hiPSC derivation and characterization, (3) assessing whether mutations or other alterations introduced by reprogramming confound interpretation, (4) developing efficient differentiation strategies to relevant cell types, (5) identifying discernible cellular phenotypes meaningful for cyclic, stress induced or relapsing–remitting diseases, (6) converting phenotypes to screening assays suitable for genome-wide mechanistic studies or large collection compound testing and (7) controlling for variability in relation to disease specificity amidst low sample numbers. Coordination of material for reprogramming from patients well-characterized clinically, genetically and with neuroimaging are beginning, and initial studies have begun to identify cellular phenotypes. Finally, several psychiatric drugs have been found to alter reprogramming efficiency in vitro, suggesting further complexity in applying hiPSCs to psychiatric diseases or that some drugs influence neural differentiation moreso than generally recognized. Despite these challenges, studies utilizing hiPSCs may eventually serve to fill essential niches in the translational pipeline for the discovery of new therapeutics. Stem cell-derived neurons could accelerate discovery of psychiatric drugs and help clinicians to provide optimal treatment for their patients. Individuals with mental illness have limited therapeutic options, and many endure months of unsuccessful treatment before finding an effective drug. A review from Evan Snyder and colleagues at the Sanford-Burnham Medical Research Institute, USA, explored the potential of human induced pluripotent stem cells (hiPSCs) as a tool for providing patients with better options. Closely resembling embryonic stem cells, hiPSCs are derived by reprogramming cells from mature tissue. This means a skin biopsy can be transformed into patient-specific neural tissue, which could be used to determine a given drug's mechanism of action with respect to that particular patient's disease state. With additional insights into the cellular basis of psychiatric disease, hiPSC-derived neurons could also assist in finding new drugs that repair specific cellular abnormalities.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/emm.2013.124

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Cellular reprogramming of somatic cells to human-induced pluripotent stem cells (hiPSCs) may be influenced by compounds also used therapeutically in clinical psychiatry. Because introduction of exogenous genetic factors may impart mutagenesis, efforts have been made to identify chemical compounds sufficient to replace genetic factors. Interestingly, to date, few such compounds have been identified, although several are incidentally used clinically in psychiatry. Because the precise mechanism by which such compounds influence either cellular reprogramming or clinical psychiatric symptoms is yet unclear, it is therefore also unknown if there is a common mechanistic component or if dedifferentiation contributes directly to therapeutic action of the drugs. Interestingly, the antidepressant tranylcypromine, and lithium to some degree, is thought to impinge on lysine-specific demethylase 1 in the regulation of histone methylation, which may also influence reprogramming. Lithium, a first-line treatment of bipolar disorder known to exhibit an inhibitory effect on GSK3β, and this in turn has been implicated by numerous studies in reprogramming of mouse cells. Valproic acid, a commonly prescribed mood stabilizer, is a histone deacetylase inhibitor, has also been widely used to increase efficiency of reprogramming (figure illustrations by Rachel Krupa).
Figure 1 Cellular reprogramming of somatic cells to human-induced pluripotent stem cells (hiPSCs) may be influenced by compounds also used therapeutically in clinical psychiatry. Because introduction of exogenous genetic factors may impart mutagenesis, efforts have been made to identify chemical compounds sufficient to replace genetic factors. Interestingly, to date, few such compounds have been identified, although several are incidentally used clinically in psychiatry. Because the precise mechanism by which such compounds influence either cellular reprogramming or clinical psychiatric symptoms is yet unclear, it is therefore also unknown if there is a common mechanistic component or if dedifferentiation contributes directly to therapeutic action of the drugs. Interestingly, the antidepressant tranylcypromine, and lithium to some degree, is thought to impinge on lysine-specific demethylase 1 in the regulation of histone methylation, which may also influence reprogramming. Lithium, a first-line treatment of bipolar disorder known to exhibit an inhibitory effect on GSK3β, and this in turn has been implicated by numerous studies in reprogramming of mouse cells. Valproic acid, a commonly prescribed mood stabilizer, is a histone deacetylase inhibitor, has also been widely used to increase efficiency of reprogramming (figure illustrations by Rachel Krupa).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 82

  1. Carpenter WT Koenig JI The evolution of drug development in schizophrenia: past issues and future opportunities Neuropsychopharmacology 2008 33 2061 2079 18046305 PMC2575138 · DOI · Paper page
  2. Barnes TR Paton C Antipsychotic polypharmacy in schizophrenia: benefits and risks CNS Drugs 2011 25 383 399 21476610 · DOI · Paper page
  3. Zink M Englisch S Meyer-Lindenberg A Polypharmacy in schizophrenia Curr Opin Psychiatry 2010 23 103 111 20051861 · DOI · Paper page
  4. Becker RE Greig NH Lost in translation: neuropsychiatric drug development Sci Transl Med 2010 2 61rv6 PMC5178822 21148128 · DOI
  5. Cowen PJ Serotonin and depression: pathophysiological mechanism or marketing myth Trends Pharmacol Sci 2008 29 433 436 18585794 · DOI · Paper page
  6. Mostert JP Koch MW Heerings M Heersema DJ De Keyser J Therapeutic potential of fluoxetine in neurological disorders CNS Neurosci Ther 2008 14 153 164 18482027 PMC6494017 · DOI · Paper page
  7. Krishnan A Hariharan R Nair SA Pillai MR Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1 Biochem Pharmacol 2008 75 1924 1934 18371935 · DOI
  8. Beaulieu JM Caron MG Looking at lithium: molecular moods and complex behaviour Mol Interv 2008 8 230 241 19015387 · DOI · Paper page
  9. Pardo R Andreolotti AG Ramos B Picatoste F Claro E Opposed effects of lithium on the MEK-ERK pathway in neural cells: inhibition in astrocytes and stimulation in neurons by GSK3 independent mechanisms J Neurochem 2003 87 417 426 14511119 · DOI · Paper page
  10. Catapano LA Manji HK Kinases as drug targets in the treatment of bipolar disorder Drug Discov Today 2008 13 295 302 18405841 · DOI
  11. Tardito D Tiraboschi E Kasahara J Racagni G Popoli M Reduced CREB phosphorylation after chronic lithium treatment is associated with down-regulation of CaM kinase IV in rat hippocampus Int J Neuropsychopharmacol 2007 10 491 496 16923323 · DOI · Paper page
  12. Hahn CG Friedman E Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder Bipolar Disord 1999 1 81 86 11252663 · DOI · Paper page
  13. Quiroz JA Machado-Vieira R Zarate CA Jr Manji HK Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects Neuropsychobiology 2010 62 50 60 20453535 PMC2889681 · DOI · Paper page
  14. McCarthy MJ Leckband SG Kelsoe JR Pharmacogenetics of lithium response in bipolar disorder Pharmacogenomics 2010 11 1439 1465 21047205 · DOI · Paper page
  15. Camins A Crespo-Biel N Junyent F Verdaguer E Canudas AM Pallas M Calpains as a target for therapy of neurodegenerative diseases: putative role of lithium Curr Drug Metab 2009 10 433 447 19689241 · DOI · Paper page
  16. Perlis RH Smoller JW Ferreira MA McQuillin A Bass N Lawrence J A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder Am J Psychiatry 2009 166 718 725 19448189 PMC3908470 · DOI · Paper page
  17. Antonelli A Ferrari SM Fallahi P Berti P Materazzi G Barani L Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests Clin Endocrinol (Oxf) 2008 69 148 152 18194485 · DOI · Paper page
  18. Bagriacik EU Baykaner MK Yaman M Sivrikaya G Durdag E Emmez H Establishment of a primary pleomorphic xanthoastrocytoma cell line: in vitro responsiveness to some chemotherapeutics Neurosurgery 2011 70 188 197 21629132 · doi:10.1227/neu.0b013e3182262c5b
  19. Basu D Montone KT Wang LP Gimotty PA Hammond R Diehl JA Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas Cell Cycle 2011 10 2008 2016 21558812 PMC3154419 · DOI
  20. Suzuki M Ishikawa H Tanaka A Mataga I Heterogeneity of anticancer drug sensitivity in squamous cell carcinoma of the tongue Hum Cell 2011 24 21 29 21547692 · doi:10.1007/s13577-010-0004-x
  21. Liu R Hsieh CY Lam KS New approaches in identifying drugs to inactivate oncogene products Semin Cancer Biol 2004 14 13 21 14757532 · doi:10.1016/j.semcancer.2003.11.003
  22. Thomson JA Itskovitz-Eldor J Shapiro SS Waknitz MA Swiergiel JJ Marshall VS Embryonic stem cell lines derived from human blastocysts Science 1998 282 1145 1147 9804556 · DOI · Paper page
  23. Cai J Li W Su H Qin D Yang J Zhu F Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells J Biol Chem 2010 285 11227 11234 20139068 PMC2857000 · DOI · Paper page
  24. Kaneko S Otsu M Nakauchi H Reprogramming adult hematopoietic cells Curr Opin Hematol 2010 17 271 275 20571391 · DOI
  25. Kim JB Greber B Arauzo-Bravo MJ Meyer J Park KI Zaehres H Direct reprogramming of human neural stem cells by OCT4 Nature 2009 461 649 3 19718018 · DOI · Paper page
  26. Unternaehrer JJ Daley GQ Induced pluripotent stem cells for modelling human diseases Philos Trans R Soc Lond Ser B 2011 366 2274 2285 21727133 PMC3130418 · DOI · Paper page
  27. Takahashi K Okita K Nakagawa M Yamanaka S Induction of pluripotent stem cells from fibroblast cultures Nat Protoc 2007 2 3081 3089 18079707 · DOI · Paper page
  28. Chiang CH Su Y Wen Z Yoritomo N Ross CA Margolis RL Integration-free induced pluripotent stem cells derived from schizophrenia patients with a DISC1 mutation Mol Psychiatry 2011 16 358 360 21339753 PMC4005725 · DOI · Paper page
  29. Sidhu KS New approaches for the generation of induced pluripotent stem cells Expert Opin Biol Ther 2011 11 569 579 21314494 · DOI
  30. Muller FJ Schuldt BM Williams R Mason D Altun G Papapetrou EP A bioinformatic assay for pluripotency in human cells Nat Methods 2011 8 315 317 21378979 PMC3265323 · DOI · Paper page
  31. Howden SE Gore A Li Z Fung HL Nisler BS Nie J Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy Proc Natl Acad Sci USA 2011 108 6537 6542 21464322 PMC3080993 · DOI · Paper page
  32. Robicsek O Karry R Petit I Salman-Kesner N Muller FJ Klein E Abnormal neuronal differentiation and mitochondrial dysfunction in hair follicle-derived induced pluripotent stem cells of schizophrenia patients Mol Psychiatry 2013 18 1067 1076 23732879 · DOI · Paper page
  33. Yeo GW Coufal N Aigner S Winner B Scolnick JA Marchetto MC Multiple layers of molecular controls modulate self-renewal and neuronal lineage specification of embryonic stem cells Hum Mol Genet 2008 17 R67 R75 18632700 · DOI
  34. Dhara SK Stice SL Neural differentiation of human embryonic stem cells J Cell Biochem 2008 105 633 640 18759328 PMC2574851 · DOI · Paper page
  35. Li W Sun W Zhang Y Wei W Ambasudhan R Xia P Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors Proc Natl Acad Sci USA 2011 108 8299 8304 21525408 PMC3100988 · DOI · Paper page
  36. Lee G Chambers SM Tomishima MJ Studer L Derivation of neural crest cells from human pluripotent stem cells Nat Protoc 2010 5 688 701 20360764 · DOI · Paper page
  37. Chambers SM Fasano CA Papapetrou EP Tomishima M Sadelain M Studer L Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling Nat Biotechnol 2009 27 275 280 19252484 PMC2756723 · DOI · Paper page
  38. Nguyen HN Byers B Cord B Shcheglovitov A Byrne J Gujar P LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress Cell Stem Cell 2011 8 267 280 21362567 PMC3578553 · DOI · Paper page
  39. Hargus G Cooper O Deleidi M Levy A Lee K Marlow E Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats Proc Natl Acad Sci USA 2010 107 15921 15926 20798034 PMC2936617 · DOI · Paper page
  40. Emdad L D'Souza SL Kothari HP Qadeer ZA Germano IM Efficient differentiation of human embryonic and induced pluripotent stem cells into functional astrocytes Stem Cells Dev 2012 21 404 410 21631388 · DOI · Paper page
  41. Hussein SM Batada NN Vuoristo S Ching RW Autio R Narva E Copy number variation and selection during reprogramming to pluripotency Nature 2011 471 58 62 21368824 · DOI · Paper page
  42. Mayshar Y Ben-David U Lavon N Biancotti JC Yakir B Clark AT Identification and classification of chromosomal aberrations in human induced pluripotent stem cells Cell Stem Cell 2010 7 521 531 20887957 · DOI · Paper page
  43. Boulting GL Kiskinis E Croft GF Amoroso MW Oakley DH Wainger BJ A functionally characterized test set of human induced pluripotent stem cells Nat Biotechnol 2011 29 279 286 21293464 PMC3229307 · DOI · Paper page
  44. Hu BY Weick JP Yu J Ma LX Zhang XQ Thomson JA Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency Proc Natl Acad Sci USA 2010 107 4335 4340 20160098 PMC2840097 · DOI · Paper page
  45. Kim JE O'Sullivan ML Sanchez CA Hwang M Israel MA Brennand K Investigating synapse formation and function using human pluripotent stem cell-derived neurons Proc Natl Acad Sci USA 2011 108 3005 3010 21278334 PMC3041068 · DOI · Paper page
  46. Caiazzo M Dell'anno MT Dvoretskova E Lazarevic D Taverna S Leo D Direct generation of functional dopaminergic neurons from mouse and human fibroblasts Nature 2011 476 224 227 21725324 · DOI · Paper page
  47. Vierbuchen T Ostermeier A Pang ZP Kokubu Y Sudhof TC Wernig M Direct conversion of fibroblasts to functional neurons by defined factors Nature 2010 463 1035 1041 20107439 PMC2829121 · DOI · Paper page
  48. Kim J Efe JA Zhu S Talantova M Yuan X Wang S Direct reprogramming of mouse fibroblasts to neural progenitors Proc Natl Acad Sci USA 2011 108 7838 7843 21521790 PMC3093517 · DOI · Paper page
  49. Kim KS Lee HJ Jeong HS Li J Teng YD Sidman RL Self-renewal induced efficiently, safely, and effective therapeutically with one regulatable gene in a human somatic progenitor cell Proc Natl Acad Sci USA 2011 108 4876 4881 21378266 PMC3064385 · doi:10.1073/pnas.1019743108
  50. Zhao T Zhang ZN Rong Z Xu Y Immunogenicity of induced pluripotent stem cells Nature 2011 474 212 215 21572395 · DOI · Paper page
  51. Nestler EJ Hyman SE Animal models of neuropsychiatric disorders Nat Neurosci 2010 13 1161 1169 20877280 PMC3750731 · DOI · Paper page
  52. Ryder PV Faundez V Schizophrenia: the ‘BLOC' may be in the endosomes Sci Signal 2009 2 pe66 19843956 PMC5696790 · DOI
  53. Henning U Krieger K Loeffler S Rivas F Orozco G de Castro MG Increased levels of glucocorticoid receptors and enhanced glucocorticoid receptor auto-regulation after hydrocortisone challenge in B-lymphoblastoids from patients with affective disorders Psychoneuroendocrinology 2005 30 325 332 15694112 · DOI
  54. D'Aiuto L Di Maio R Heath B Raimondi G Milosevic J Watson AM Human induced pluripotent stem cell-derived models to investigate human cytomegalovirus infection in neural cells PLoS One 2012 7 e49700 23209593 PMC3507916 · DOI
  55. Basta-Kaim A Budziszewska B Jaworska-Feil L Tetich M Kubera M Leskiewicz M Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases Neuropsychopharmacology 2006 31 853 865 16205782 · DOI
  56. Kurosawa S Hashimoto E Ukai W Toki S Saito S Saito T Olanzapine potentiates neuronal survival and neural stem cell differentiation: regulation of endoplasmic reticulum stress response proteins J Neural Transm 2007 114 1121 1128 17557129 · DOI
  57. Hashimoto R Senatorov V Kanai H Leeds P Chuang DM Lithium stimulates progenitor proliferation in cultured brain neurons Neuroscience 2003 117 55 61 12605892 · DOI
  58. Laeng P Pitts RL Lemire AL Drabik CE Weiner A Tang H The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells J Neurochem 2004 91 238 251 15379904 · DOI · Paper page
  59. Hisaoka K Maeda N Tsuchioka M Takebayashi M Antidepressants induce acute CREB phosphorylation and CRE-mediated gene expression in glial cells: a possible contribution to GDNF production Brain Res 2008 1196 53 58 18234163 · DOI
  60. Zhou X Barrett TB Kelsoe JR Promoter variant in the GRK3 gene associated with bipolar disorder alters gene expression Biol Psychiatry 2008 64 104 110 18359007 PMC6528791 · DOI
  61. Huang W Li MD Differential allelic expression of dopamine D1 receptor gene (DRD1) is modulated by microRNA miR-504 Biol Psychiatry 2009 65 702 705 19135651 PMC2678413 · DOI · Paper page
  62. Yoshikawa A Shimada H Numazawa K Sasaki T Ikeda M Kawashima M Establishment of human cell lines showing circadian rhythms of bioluminescence Neurosci Lett 2008 446 40 44 18809466 · DOI
  63. Kowalska E Moriggi E Bauer C Dibner C Brown SA The circadian clock starts ticking at a developmentally early stage J Biol Rhythms 2010 25 442 449 21135160 · DOI · Paper page
  64. Kiselyuk A Farber-Katz S Cohen T Lee SH Geron I Azimi B Phenothiazine neuroleptics signal to the human insulin promoter as revealed by a novel high-throughput screen J Biomol Screen 2010 15 663 670 20547533 PMC3374493 · DOI
  65. Kiris E Nuss JE Burnett JC Kota KP Koh DC Wanner LM Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery Stem Cell Res 2011 6 195 205 21353660 PMC3081902 · doi:10.1016/j.scr.2011.01.002
  66. Lynch WP Sharpe AH Snyder EY Neural stem cells as engraftable packaging lines can mediate gene delivery to microglia: evidence from studying retroviral env-related neurodegeneration J Virol 1999 73 6841 6851 10400782 PMC112769 · DOI
  67. Lynch WP Snyder EY Qualtiere L Portis JL Sharpe AH Late virus replication events in microglia are required for neurovirulent retrovirus-induced spongiform neurodegeneration: evidence from neural progenitor-derived chimeric mouse brains J Virol 1996 70 8896 8907 8971019 PMC190987 · doi:10.1128/jvi.70.12.8896-8907.1996
  68. Tobe BT Snyder EY Nye JS Modeling complex neuropsychiatric disorders with human induced pluripotent stem cells Curr Opin Pharmacol 2011 11 521 527 21723195 PMC3428145 · DOI
  69. Huangfu D Osafune K Maehr R Guo W Eijkelenboom A Chen S Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2 Nat Biotechnol 2008 26 1269 1275 18849973 · DOI · Paper page
  70. Lyssiotis CA Foreman RK Staerk J Garcia M Mathur D Markoulaki S Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4 Proc Natl Acad Sci USA 2009 106 8912 8917 19447925 PMC2690053 · DOI · Paper page
  71. Wang Q Xu X Li J Liu J Gu H Zhang R Lithium, an anti-psychotic drug, greatly enhances the generation of induced pluripotent stem cells Cell Res 2011 21 1424 1435 21727907 PMC3193456 · DOI · Paper page
  72. Deng J Shoemaker R Xie B Gore A LeProust EM Antosiewicz-Bourget J Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming Nat Biotechnol 2009 27 353 360 19330000 PMC2715272 · DOI · Paper page
  73. Yamanaka S Elite and stochastic models for induced pluripotent stem cell generation Nature 2009 460 49 52 19571877 · DOI · Paper page
  74. Plath K Lowry WE Progress in understanding reprogramming to the induced pluripotent state Nat Rev Genet 2011 12 253 265 21415849 PMC3273493 · DOI · Paper page
  75. Pidsley R Mill J Epigenetic studies of psychosis: current findings, methodological approaches, and implications for postmortem research Biol Psychiatry 2011 69 146 156 20510393 · DOI
  76. Yang M Culhane JC Szewczuk LM Jalili P Ball HL Machius M Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine Biochemistry 2007 46 8058 8065 17569509 · DOI · Paper page
  77. Karytinos A Forneris F Profumo A Ciossani G Battaglioli E Binda C A novel mammalian flavin-dependent histone demethylase J Biol Chem 2009 284 17775 17782 19407342 PMC2719416 · DOI · Paper page
  78. Li W Zhou H Abujarour R Zhu S Young Joo J Lin T Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2 Stem Cells 2009 27 2992 3000 19839055 PMC3780784 · DOI · Paper page
  79. Perisic T Zimmermann N Kirmeier T Asmus M Tuorto F Uhr M Valproate and amitriptyline exert common and divergent influences on global and gene promoter-specific chromatin modifications in rat primary astrocytes Neuropsychopharmacology 2010 35 792 805 19924110 PMC3055607 · DOI
  80. Yu IT Park JY Kim SH Lee JS Kim YS Son H Valproic acid promotes neuronal differentiation by induction of proneural factors in association with H4 acetylation Neuropharmacology 2009 56 473 480 19007798 · DOI · Paper page
  81. Hester ME Song S Miranda CJ Eagle A Schwartz PH Kaspar BK Two factor reprogramming of human neural stem cells into pluripotency PLoS One 2009 4 e7044 19763260 PMC2739296 · DOI · Paper page
  82. Okita K Matsumura Y Sato Y Okada A Morizane A Okamoto S A more efficient method to generate integration-free human iPS cells Nat Methods 2011 8 409 412 21460823 · DOI · Paper page

Cited by

See all 9

Metadata

Authors
Tobe, B. T. D., Brandel, M. G., Nye, J. S., & Snyder, E. Y.
Venue
Experimental & Molecular Medicine
Published
2013-11-15
Volume
45
Issue
11
Pages
e59-e59
ISSN
2092-6413
Cited by
9
References
18
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.